Abstract
P-glycoprotein (P-gp), a cell membrane protein, has been found in multidrug-resistant cancer cells. A total of 104 smears from patients with breast-cancer-associated pleural effusions and ovarian-cancer-related peritoneal effusions were studied for P-gp with the antibody C-219 and the avidin-biotin-immunoperoxidase method. Samples were taken before and 3 and 7 days after intracavitary bleomycin therapy and reaccumulation of effusion was assessed at 30 days. Smears that were P-gp-negative by the 7th day were associated with a good 30-day response to bleomycin in the majority of cases, while P-gp-positive smears were associated with a significant reaccumulation of fluid at 30 days. P-gp status is a valuable prognostic indicator of response to intracavitary bleomycin treatment in effusions from breast or ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- P-gp :
-
P-glycoprotein
References
Athanassiadou P, Athanassiades P, Giannioti H, Kyrkou K (1991) Immunocytochemical expression of P-glycoprotein in pleural and peritoneal tumor cells and anti neoplastic drug resistance Eur J Cancer 27 [Suppl 2]: 1307
Bezwoda W, Seymour L, Dansey R (1989) Intraperitoneal recombinant interferon-α 2b for recurrent malignant ascites due to ovarian cancer. Cancer 64:1029–1033
Bitran J (1985) Intraperitoneal bleomycin: pharmacokinetics and results of a phase II trial. Cancer 56:2420–2423
Bitran J, Brown C, Desser R, Kozloff M, Shapiro C, Billings A (1981) Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol 16:273–277
Chatterjee M, Robson C, Harris A (1990) Reversal of multidrug resistance by verapamil and modulation by al acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. Cancer Res 50:2818–2822
D'lncolci M, Broxterman H, Kalken C van (1991) Membrane transport in multidrug resistance, development and disease. Ann Oncol 2:635–639
Duensing S, Dallmann I, Grosse J, Buer J, Lopez-Hanninen E, Deckert M, Storkel S, Kirchner H, Poliwoda H, Atzpodien J (1994) Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 51:309–313
Fuqua S, Moretti-Rojas I, Schneider S, McGuire W (1987) P-glycoprotein expression in human breast cancer cells. Cancer Res 47:2103–2106
Hamed H, Fentiman IS, Chaudary MA, Rubens RD (1989) Comparison of intracavitary Bleomycin talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg 76:1266–1267
Hsu S, Raine L, Fanges H (1991) Use of avidin biotin peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580
Juliano R, Ling V (1976) A surface-glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162
Kartner N, Ling V (1989) Multidrug resistance in cancer. Sci Am 26–33
Ostrowski MJ (1986) An assessment of the long term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 57:721–727
Ostrowski M, Halsall G (1982) Intracavitary bleomycin in the management of malignant effusions: a multicentre study. Cancer Treat Rep 66:1903–1907
Paladine W, Cunningham T, Sponzo R, Donavan M, Olson K, Horton J (1976) Intracavitary bleomycin in the management of malignant effusions. Cancer 38:1903–1908
Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393
Pretorius G, Hacher F, Bervk S, et al. (1981) The pharmacokinetics of intraperitoneal cis-platinum in refractory ovarian cancer. Obstet Gynecol 58:192–198
Ro J, Sahin A, Ro J, Fritsche H, Hortobagyl G, Blick M (1990) Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787–791
Roberts P, Penny J, Campbell F (1995) Chemosensitisation of human adenocarcinoma cells by antisense against the multidrug resistance (MDR 1) gene. Eur J Cancer 31A [Suppl 5]: S26
Rutledge M, Robey-Cafferty S, Silva E, Bruner J (1990) Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Mod Pathol 3:298–301
Sicik B (1993) Bleomycin. In: Cuitkovic E, Droz J, Armand J, Khoury S (eds) Handbook of chemotherapy in clinical oncology. Scientific Communication International, Paris, pp 296–302
Takeshita H, Gebhardt C, Springfield S, et al. (1996) Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am 3:366–375
Verrelle P, Meissonnier F, Fonck Y, et al. (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116
Weinstein R, Kuszak J, Kluskens L, Coon J (1990) P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21:34–48
West R, Boyle E, Grignon D, Chin-Yee I (1994) P-glycoprotein expression in non-Hodgkin's lymphoma. Int J Oncol 4:1237–1242
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Athanassiadou, P., Athanassiades, P., Petrakakou, E. et al. Immunocytochemical detection of P-glycoprotein in the management of malignant effusions. J Cancer Res Clin Oncol 123, 456–460 (1997). https://doi.org/10.1007/BF01372551
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01372551